Mantinex (Memantine Hydrochloride)

• Mantinex is a NMDA‑receptor antagonist used in the management of Alzheimer’s disease, a neurodegenerative disorder affecting cognition and function.
• Alzheimer’s disease (moderate to severe): improves cognition, daily living activities and overall clinical status.
• Alzheimer’s disease (moderate): supports maintenance of functional abilities.
• Alzheimer’s disease (severe): helps slow further cognitive decline.

• Memantine hydrochloride acts as a non‑competitive antagonist at the NMDA (N‑methyl‑D‑aspartate) receptor. By binding to the receptor-associated ion channel, it reduces excessive calcium influx caused by glutamate over‑activation, thereby decreasing excitotoxic neuronal injury and helping preserve synaptic function in the brain.

Common Side Effects

• Dizziness: mild to moderate sensation of light‑headedness.
• Headache: occasional tension‑type headache.
• Constipation: reduced bowel movements.
• Fatigue: feeling of tiredness or low energy.
• Nausea: mild upset stomach.
• Cough: dry or non‑productive cough.

Serious or Rare Side Effects

• Seizures: rare occurrence of convulsive episodes.
• Severe allergic reaction: rash, itching, swelling, or breathing difficulty.
• Hallucinations: visual or auditory disturbances.
• Mood changes: depression or suicidal thoughts.
• Hyponatremia: low blood sodium levels.
• Liver enzyme elevation: abnormal liver function tests.

Before initiating therapy, consider patient history, concomitant conditions, and monitoring requirements.

• Renal impairment: dose may need adjustment; monitor kidney function.
• Hepatic disease: use with caution; assess liver enzymes.
• Cardiovascular disease: monitor blood pressure and heart rate.
• Psychiatric disorders: observe for mood changes or hallucinations.
• Drug interactions: review concomitant medications for potential interactions.
• Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and direct sunlight.

Memantine may interact with several medicines, requiring careful assessment.

Major Interactions (Avoid)

• Amantadine: combined use can increase risk of dizziness and confusion.
• Ketamine: additive NMDA antagonism may enhance neuropsychiatric effects.
• High‑dose quinidine: may raise memantine plasma levels.

Moderate Interactions (Monitor Closely)

• Anticholinergic agents: may reduce therapeutic benefit.
• CNS depressants (e.g., benzodiazepines): may increase sedation.
• Proton pump inhibitors: may slightly increase memantine exposure.
• Antihypertensives: monitor blood pressure for additive effects.